Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 4 | 11 |
| 1.1 List of Tables | 9 | 3 |
| 1.2 List of Figures | 12 | 3 |
| 2 Introduction | 15 | 2 |
| 2.1 GBI Research Report Guidance | 16 | 1 |
| 3 Global Biotechnology Industry Market Characterization | 17 | 7 |
| 3.1 Global Biotechnology Industry Market Size | 17 | 1 |
| 3.2 Top 10 Companies Market Forecast | 18 | 2 |
| 3.3 Therapeutic Focus of the Biotechnology Industry | 20 | 2 |
| 3.4 Global Biotechnology Industry Growth Drivers and Restraints | 22 | 1 |
| 3.4.1 Growth Drivers | 22 | 1 |
| 3.4.1.1 High Unmet Need Driving Market Growth | 22 | 1 |
| 3.4.1.2 Huge Investments in R&D Resulting In Strong Product Pipeline | 22 | 1 |
| 3.4.1.3 Strong Growth in the Market for Cancer and Autoimmune Diseases | 22 | 1 |
| 3.4.1.4 Lack of Patent Expiry Ensures a Continuous Stream Of Revenue | 22 | 1 |
| 3.4.1.5 Increasing Interest of Big Pharma Companies in Biotechnology Industry | 23 | 1 |
| 3.4.2 Restraints | 23 | 1 |
| 3.4.2.1 High Cost of Treatment of Biologics | 23 | 1 |
| 3.4.2.2 Increasing Incidences of Adverse Side Effects | 23 | 1 |
| 3.4.2.3 Threat from Biosimilars | 23 | 1 |
| 4 Top 10 Biotechnology Companies Competitive Landscape | 24 | 6 |
| 4.1 Competitive Landscape Framework | 24 | 1 |
| 4.2 Financial Benchmarking | 25 | 1 |
| 4.2.1 Earnings per Share | 26 | 1 |
| 4.2.2 Net Profit Margin | 26 | 1 |
| 4.2.3 Current Ratio | 27 | 1 |
| 4.2.4 Debt to Equity ratio | 27 | 1 |
| 4.2.5 Asset Turnover Ratio | 28 | 1 |
| 4.3 R&D Productivity Framework | 28 | 2 |
| 5 Global Biotechnology Industry Strategic Consolidations | 30 | 3 |
| 5.1 Pharma Biotech Space Deals Analysis (2008) | 30 | 1 |
| 5.2 Increasing Interest of Big Pharma Companies in the Biotech Industry | 31 | 2 |
| 6 Top 10 Biotechnology Companies Amgen | 33 | 17 |
| 6.1 Company Overview | 33 | 1 |
| 6.1.1 Introduction | 33 | 1 |
| 6.1.2 Business Description | 33 | 1 |
| 6.2 Strategic Positioning | 34 | 1 |
| 6.2.1 SWOT Analysis | 34 | 1 |
| 6.2.1.1 Strengths - Strong Marketed and Pipeline Products Drive Amgen s Revenues | 34 | 1 |
| 6.2.1.2 Weaknesses - Market Is Declining for Its Key Products like Aranesp and Epogen | 35 | 1 |
| 6.2.1.3 Opportunities - High Growth in Oncology Therapeutics Market Presents Immense Opportunities | 35 | 1 |
| 6.2.1.4 Threats - Safety Concerns Are Looming Over the Use of Esas in Patients | 35 | 1 |
| 6.3 Financial Analysis | 36 | 1 |
| 6.3.1 Revenue Analysis and Forecasts | 36 | 3 |
| 6.3.2 Ratio Analysis | 39 | 1 |
| 6.3.2.1 Equity Ratios | 39 | 1 |
| 6.3.2.2 Profitability Ratios | 40 | 1 |
| 6.3.2.3 Liquidity Ratios | 41 | 1 |
| 6.3.2.4 Leverage Ratios | 42 | 1 |
| 6.3.2.5 Efficiency Ratios | 42 | 1 |
| 6.3.3 DuPont Analysis | 43 | 1 |
| 6.4 Marketed Products | 44 | 1 |
| 6.4.1 Key Marketed Products | 44 | 1 |
| 6.4.1.1 Enbrel | 44 | 1 |
| 6.4.1.2 Aranesp | 44 | 1 |
| 6.4.1.3 Epogen | 44 | 1 |
| 6.4.1.4 Neulasta | 44 | 1 |
| 6.4.1.5 Neupogen | 44 | 1 |
| 6.5 R&D Strategies | 45 | 1 |
| 6.5.1 Therapeutic Focus | 45 | 1 |
| 6.5.2 R&D Productivity | 46 | 1 |
| 6.6 Product Pipeline | 47 | 1 |
| 6.6.1 Overview | 47 | 1 |
| 6.6.2 Key Pipeline Products | 48 | 1 |
| 6.6.2.1 Denosumab | 48 | 1 |
| 6.6.2.2 Motesanib | 48 | 1 |
| 6.6.2.3 Aranesp | 48 | 1 |
| 6.6.2.4 Sensipar | 48 | 1 |
| 6.7 Licensing Agreements | 49 | 1 |
| 6.7.1 Overview | 49 | 1 |
| 7 Top 10 Biotechnology Companies Genentech (Roche) | 50 | 16 |
| 7.1 Company Overview | 50 | 1 |
| 7.1.1 Introduction | 50 | 1 |
| 7.1.2 Business Description | 50 | 1 |
| 7.2 Strategic Positioning | 51 | 1 |
| 7.2.1 SWOT Analysis | 51 | 1 |
| Strengths - Monoclonal Antibodies in Cancer Therapeutics Market Driving Growth | 51 | 1 |
| 7.2.1.2 Weaknesses - Relationship with Roche Might Restrict Geographical Expansion | 51 | 1 |
| 7.2.1.3 Opportunities - Promising future in oncology therapeutics and small molecule therapies | 52 | 1 |
| 7.2.1.4 Threats Entry of Biosimilars in Oncology Pose a Threat To Company s Revenues | 52 | 1 |
| 7.3 Financial Analysis | 52 | 1 |
| 7.3.1 Revenue Analysis and Forecasts | 52 | 3 |
| 7.3.2 Ratio Analysis | 55 | 1 |
| 7.3.2.1 Equity Ratios | 55 | 1 |
| 7.3.2.2 Profitability Ratios | 56 | 1 |
| 7.3.2.3 Liquidity Ratios | 57 | 1 |
| 7.3.2.4 Leverage Ratios | 58 | 1 |
| 7.3.2.5 Efficiency Ratios | 59 | 1 |
| 7.3.3 DuPont Analysis | 59 | 1 |
| Marketed Products | 60 | 1 |
| 7.4.1 Key Marketed Products | 60 | 1 |
| 7.4.1.1 Avastin | 60 | 1 |
| 7.4.1.2 Rituxan | 60 | 1 |
| 7.4.1.3 Herceptin | 60 | 1 |
| 7.4.1.4 Lucentis | 60 | 1 |
| 7.5 R&D Strategies | 61 | 1 |
| Therapeutic Focus | 61 | 1 |
| 7.5.2 R&D Productivity | 61 | 1 |
| 7.6 Product Pipeline | 62 | 1 |
| 7.6.1 Overview | 62 | 2 |
| 7.6.2 Key Pipeline Products | 64 | 1 |
| 7.6.2.1 Avastin | 64 | 1 |
| 7.6.2.2 Ocrelizumab (2nd Generation Anti-D20) | 64 | 1 |
| 7.6.2.3 Tarceva | 64 | 1 |
| 7.7 Licensing Agreements | 64 | 1 |
| 7.7.1 Overview | 64 | 2 |
| 8 Top 10 Biotechnology Companies Gilead Sciences | 66 | 14 |
| 8.1 Company Overview | 66 | 1 |
| Introduction | 66 | 1 |
| 8.1.2 Business Description | 66 | 1 |
| 8.2 Strategic Positioning | 67 | 1 |
| 8.2.1 SWOT Analysis | 67 | 1 |
| 8.2.1.1 Strengths - Gilead Is the Market Leader in the Global HIV Therapeutics Market | 67 | 1 |
| 8.2.1.2 Weaknesses - Product Portfolio of Gilead Lacks Diversification | 67 | 1 |
| 8.2.1.3 Opportunities - Strong Growth Is Expected In the HIV Therapeutics Market | 68 | 1 |
| 8.2.1.4 Threats - Competitors Are Collaborating to Challenge Gilead s Leadership | 68 | 1 |
| 8.3 Financial Analysis | 68 | 1 |
| 8.3.1 Revenue Analysis and Forecasts | 68 | 3 |
| 8.3.2 Ratio Analysis | 71 | 1 |
| 8.3.2.1 Equity Ratios | 71 | 1 |
| 8.3.2.2 Profitability Ratios | 71 | 2 |
| 8.3.2.3 Liquidity Ratios | 73 | 1 |
| 8.3.2.4 Leverage Ratios | 74 | 1 |
| 8.3.2.5 Efficiency Ratios | 74 | 1 |
| 8.3.3 DuPont Analysis | 75 | 1 |
| 8.4 Marketed Products | 76 | 1 |
| 8.4.1 Key Marketed Products | 76 | 1 |
| 8.4.1.1 Truvada | 76 | 1 |
| Atripla | 76 | 1 |
| 8.4.1.3 Viread | 76 | 1 |
| 8.5 R&D Strategies | 76 | 1 |
| 8.5.1 Therapeutic Focus | 76 | 1 |
| 8.5.2 R&D Productivity | 77 | 1 |
| 8.6 Product Pipeline | 78 | 1 |
| 8.6.1 Overview | 78 | 1 |
| 8.6.2 Key Pipeline Products | 79 | 1 |
| 8.6.2.1 Aztreonam | 79 | 1 |
| 8.6.2.2 Elvitegravir | 79 | 1 |
| 8.6.2.3 Darusentan | 79 | 1 |
| 8.7 Licensing Agreements | 79 | 1 |
| 8.7.1 Overview | 79 | 1 |
| 9 Top 10 Biotechnology Companies UCB Pharma | 80 | 14 |
| 9.1 Company Overview | 80 | 1 |
| 9.1.1 Introduction | 80 | 1 |
| 9.1.2 Business Description | 80 | 1 |
| 9.2 Strategic Positioning | 81 | 1 |
| 9.2.1 SWOT Analysis | 81 | 1 |
| 9.2.1.1 Strengths - Complete Focus on Biopharmaceuticals to Drive Long Term Strategy | 81 | 1 |
| 9.2.1.2 Weaknesses - Product Recalls and Rejections Affecting Company s Brand Value | 81 | 1 |
| 9.2.1.3 Opportunities - Company s Pipeline to Present Opportunities for Growth | 82 | 1 |
| 9.2.1.4 Threats - Generics Affecting the Growth Prospects of Global Epilepsy Market | 82 | 1 |
| 9.3 Financial Analysis | 82 | 1 |
| 9.3.1 Revenue Analysis and Forecasts | 82 | 3 |
| 9.3.2 Ratio Analysis | 85 | 1 |
| 9.3.2.1 Equity Ratios | 85 | 1 |
| 9.3.2.2 Profitability Ratios | 86 | 1 |
| 9.3.2.3 Liquidity Ratios | 87 | 1 |
| 9.3.2.4 Leverage Ratios | 88 | 1 |
| 9.3.2.5 Efficiency Ratios | 88 | 1 |
| 9.3.3 DuPont Analysis | 89 | 1 |
| 9.4 Marketed Products | 90 | 1 |
| 9.4.1 Key Marketed Products | 90 | 1 |
| 9.4.1.1 Keppra/Keppra XR and Vimpat | 90 | 1 |
| Neupro | 90 | 1 |
| 9.4.1.3 Cimzia | 90 | 1 |
| 9.5 R&D Strategies | 90 | 1 |
| 9.5.1 Therapeutic Focus | 90 | 1 |
| 9.5.2 R&D Productivity | 90 | 2 |
| 9.6 Product Pipeline | 92 | 1 |
| 9.6.1 Overview | 92 | 1 |
| 9.6.2 Key Pipeline Products | 93 | 1 |
| 9.6.2.1 Brivaracetam | 93 | 1 |
| 9.6.2.2 Vimpat | 93 | 1 |
| 9.6.2.3 Epratuzumab | 93 | 1 |
| 9.7 Licensing Agreements | 93 | 1 |
| 9.7.1 Overview | 93 | 1 |
| 10 Top 10 Biotechnology Companies Genzyme | 94 | 15 |
| 10.1 Company Overview | 94 | 1 |
| 10.1.1 Introduction | 94 | 1 |
| 10.1.2 Business Description | 94 | 1 |
| 10.2 Strategic Positioning | 95 | 1 |
| 10.2.1 SWOT Analysis | 95 | 1 |
| 10.2.1.1 Strengths - Broad Product Base and Orphan Drug Status Strengthens Company s Positioning | 95 | 1 |
| 10.2.1.2 Weaknesses - Withdrawl of Evoltra in Europe Will Affect Revenues | 96 | 1 |
| 10.2.1.3 Opportunities - Cancer Therapeutics Market Will Present Growth Opportunities | 96 | 1 |
| 10.2.1.4 Threats - Competition Is Likely to Increase for Company s Lead Products | 96 | 1 |
| 10.3 Financial Analysis | 97 | 1 |
| 10.3.1 Revenue Analysis and Forecasts | 97 | 2 |
| 10.3.2 Ratio Analysis | 99 | 1 |
| 10.3.2.1 Equity Ratios | 99 | 1 |
| 10.3.2.2 Profitability Ratios | 100 | 1 |
| 10.3.2.3 Liquidity Ratios | 101 | 1 |
| 10.3.2.4 Leverage Ratios | 102 | 1 |
| 10.3.2.5 Efficiency Ratios | 102 | 1 |
| 10.3.3 DuPont Analysis | 102 | 1 |
| Marketed Products | 103 | 1 |
| 10.4.1 Key Marketed Products | 103 | 1 |
| 10.4.1.1 Cerezyme | 103 | 1 |
| 10.4.1.2 Fabrazyme | 104 | 1 |
| 10.4.1.3 Renagel and Renvela | 104 | 1 |
| 10.5 R&D Strategies | 104 | 1 |
| 10.5.1 Therapeutic Focus | 104 | 1 |
| 10.5.2 R&D Productivity | 105 | 1 |
| 10.6 Product Pipeline | 106 | 1 |
| 10.6.1 Overview | 106 | 1 |
| 10.6.2 Key Pipeline Products | 107 | 1 |
| 10.6.2.1 Alemtuzumab | 107 | 1 |
| 10.6.2.2 Mipomersen | 107 | 1 |
| 10.6.2.3 Clolar | 107 | 1 |
| 10.7 Licensing Agreements | 107 | 1 |
| 10.7.1 Overview | 107 | 2 |
| 11 Top 10 Biotechnology Companies Biogen Idec | 109 | 14 |
| 11.1 Company Overview | 109 | 1 |
| 11.1.1 Introduction | 109 | 1 |
| 11.1.2 Business Description | 109 | 1 |
| 11.2 Strategic Positioning | 110 | 1 |
| 11.2.1 SWOT Analysis | 110 | 1 |
| 11.2.1.1 Strengths - Aggressive Licensing Activities Complementing For Lack Of Global Presence | 110 | 1 |
| 11.2.1.2 Weaknesses - Excessive Reliance on A Few Products for Revenue Growth | 110 | 1 |
| 11.2.1.3 Opportunities - Cancer Therapeutics and Multiple Sclerosis Market Can Drive Growth | 111 | 1 |
| 11.2.1.4 Threats - Competition Getting Stiff for Company s Key Products | 111 | 1 |
| 11.3 Financial Analysis | 111 | 1 |
| 11.3.1 Revenue Analysis and Forecasts | 111 | 3 |
| 11.3.2 Ratio Analysis | 114 | 1 |
| 11.3.2.1 Equity Ratios | 114 | 1 |
| 11.3.2.2 Profitability Ratios | 114 | 2 |
| 11.3.2.3 Liquidity Ratios | 116 | 1 |
| 11.3.2.4 Leverage Ratios | 117 | 1 |
| 11.3.2.5 Efficiency Ratios | 117 | 1 |
| 11.3.3 DuPont Analysis | 118 | 1 |
| 11.4 Marketed Products | 119 | 1 |
| 11.4.1 Key Marketed Products | 119 | 1 |
| 11.4.1.1 Avonex | 119 | 1 |
| 11.4.1.2 Tysabri | 119 | 1 |
| 11.4.1.3 Rituxan | 119 | 1 |
| 11.5 R&D Strategies | 119 | 1 |
| 11.5.1 Therapeutic Focus | 119 | 1 |
| 11.5.2 R&D Productivity | 120 | 1 |
| 11.6 Product Pipeline | 121 | 1 |
| 11.6.1 Overview | 121 | 1 |
| 11.6.2 Key Pipeline Products | 122 | 1 |
| 11.6.2.1 Ocrelizumab | 122 | 1 |
| 11.6.2.2 PEG IFN and BG-12 | 122 | 1 |
| 11.6.2.3 Rituxan | 122 | 1 |
| 11.7 Licensing Agreements | 122 | 1 |
| 11.7.1 Overview | 122 | 1 |
| 12 Top 10 Biotechnology Companies CSL Limited | 123 | 14 |
| 12.1 Company Overview | 123 | 1 |
| 12.1.1 Introduction | 123 | 1 |
| 12.1.2 Business Description | 123 | 1 |